GleamWall
中文EN

QCLS Q/C TECHNOLOGIES, INC.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1321834 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-120.7%
TTM EPS YoY105.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-113.0%
ROA-58.8%
ROIC (approx.)-131.5%
Asset turnover—

Leverage & solvency

Liabilities / assets10.2%
Debt / equity0.00x
Current ratio5.06x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-25.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$3.47M$3.44M
SG&A expense$3.74M$4.16M
Operating income-$9.85M-$10.17M
Pretax income-$11.63M-$23.36M
Net income-$11.63M-$23.36M
EPS (basic)-8.66-1,080.87
EPS (diluted)-8.66-1,080.87
Weighted avg. shares (diluted)1.73M25,129
Balance sheet
Cash & equivalents$986,996$173,154
Short-term investments$14.80M$8.35M
Current assets$16.58M$9.41M
Goodwill$10.50M$10.50M
Intangibles$14.09M—
Total assets$41.17M$21.42M
Current liabilities$5.53M$6.70M
Total liabilities$16.44M$6.70M
Shareholders' equity$21.75M$9.79M
Shares outstanding7.69M33,636
Cash flow statement
Operating cash flow-$9.07M-$8.98M
Capital expenditure$1.75M—
Free cash flow-$10.82M—
Investing cash flow-$8.42M-$6.10M
Financing cash flow$18.30M$12.57M
Stock-based compensation$2.17M$1.06M

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.